Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Chugai’s PNH Med, Takeda’s cTTP Therapy Now in Line for Japan Approval
Chugai Pharmaceutical’s paroxysmal nocturnal hemoglobinuria (PNH) treatment crovalimab sailed through the review of a key Japanese advisory panel on February 29, setting the stage for approval in the near future along with a batch of other medicines endorsed on the…
To read the full story
Related Article
- Chugai’s PNH Med, Takeda’s cTTP Therapy Up for Advisory Panel Review on Feb. 29
February 16, 2024
- Viatris Files Cystinosis Med in Japan
September 22, 2023
- Takeda Files cTTP Therapy ADAMTS-13 in Japan
August 18, 2023
- Meiji Seika Pharma Files GVHD Drug Belumosudil in Japan
June 28, 2023
- UCB Japan Seeks Lennox-Gastaut Syndrome Indication for Fintepla
June 28, 2023
- Chugai Files NDA for PNH Drug Crovalimab in Japan
June 15, 2023
REGULATORY
- Japan Begins Review of Domestic CGT Seeds with Limited Market Potential
June 30, 2026
- Govt Panel Urges 2027 Bill to Expand Secondary Use of Health Data
June 30, 2026
- Japan Panel OKs Carvykti’s Earlier Use in Multiple Myeloma
June 30, 2026
- Govt to Explore Greater Rewards for Innovative Drugs in Honebuto
June 29, 2026
- MHLW Starts Technical Review of OTC-Like Drug Charge Exemptions
June 29, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…